TISSUE REGENIX GROUP

TRX
Delayed Quote. Delayed  - 07/01 04:35:29 pm
0.35GBX +4.79%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
Tissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes deoxyribonucleic acid and other cellular material from tissue leaving an acellular scaffold, which is not rejected by the patient's body. The dCELL has applications in wound care, heart valve replacement and knee repair. Its products portfolio includes DermaPure, which is used for the treatment of chronic or acute wounds; SurgiPure XD Surgical Tissue Matrix, which is used as a soft tissue patch for the surgical repair of damaged or ruptured soft tissue membranes; OrthoPure XM, which is used to replace the tissue removed during a partial meniscopy; OrthoPure XT, which is a decellurised porcine tendon, and CardioPure, a decellurised human pulmonary or aortic heart valve.
Sales per Business
2019
GBP
(in Million)
%
Orthopaedics & Dental 6.7251.6%
BioSurgery 4.2332.5%
GBM-V 2.0815.9%
Sales per region
20182019
GBP
(in Million)
%GBP
(in Million)
%
United States 9.4381.2% 10.6881.9%
Rest of World 2.1918.8% 2.3518.1%
Managers
Name Title
Gareth Hywel Jones CEO, COO & Executive Director
Jonathan Martin Glenn Non-Executive Chairman
Kirsten Lund Secretary & Group Finance Director
Mike Izon Director-Research & Development
Alan J. Miller Non-Executive Director
Randeep Singh Grewal Non-Executive Director
Shervanthi Homer-Vanniasinkam Non-Executive Director
Caitlin Pearson Director-Corporate Communications
Shareholders
Name Equities %
Lombard Odier Asset Management (Europe) Ltd. 835,500,001 11.9%
Premier Fund Managers Ltd. 764,414,600 10.9%
Richard Ian Griffiths 487,000,000 6.93%
SpreadEx Ltd. 370,260,176 5.27%
Jupiter Asset Management Ltd. 350,876,717 4.99%
Diverse Income Trust PLC 303,701,093 4.32%
Acacia Research Corporation 184,212,642 2.62%
IP Group Plc /Venture Capital/ 153,042,837 2.18%
Hargreaves Lansdown Stockbrokers Ltd. 131,531,000 1.87%
Invesco Asset Management Ltd. 60,000,000 0.85%
Company contact information
Tissue Regenix Group Plc
Astley Lane Industrial Estate
Astley Way
Unit 1&2, Swillington
Leeds, Yorkshire LS26 8XT

Phone : +44.330.430.3052
Fax : +44.1904.380517
Web : http://tissueregenix.com
Sector Biotechnology & Medical Research - NEC
1st jan.Capi. (M$)
TISSUE REGENIX GROUP PLC-66.60%29
LONZA GROUP41.62%39 236
CELLTRION, INC.69.06%34 116
SEATTLE GENETICS, INC.48.71%29 413
IQVIA HOLDINGS INC.-8.17%27 094
MODERNA, INC.228.27%24 966
INCYTE CORPORATION17.36%22 600
ALNYLAM PHARMACEUTICALS, INC.28.60%17 086
GALAPAGOS NV-6.14%12 855
HANGZHOU TIGERMED CONSULTING CO.,LTD61.33%10 809
PHARMARON BEIJING CO., LTD.90.92%10 582
BIO-TECHNE CORPORATION20.30%10 094
QIAGEN N.V.26.66%9 781
PPD, INC.0.00%9 342
ICON PUBLIC LIMITED COMPANY-2.19%8 846
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.10.63%8 628
IONIS PHARMACEUTICALS, INC.-2.40%8 214
IMMUNOMEDICS, INC.67.49%8 183
ACADIA PHARMACEUTICALS INC.13.30%7 555
PRA HEALTH SCIENCES, INC.-12.47%6 200
SYNEOS HEALTH, INC.-2.06%6 068